To Support MS Cannabinoid Studies, MMJ Asks US Agency to OK Shipments from Canada

MMJ International Holdings, a pharmaceutical company whose focus is plant-derived cannabis products for therapeutic purposes, has requested permission to ship tetrahydrocannabinol (THC) and cannabidiol (CBD) from Canada to the U.S. to be used in upcoming clinical trials for people with multiple sclerosis (MS) and Huntington’s disease.

MMJ-001 and MMJ-002 are among the company’s lead therapeutic candidates. MMJ-001 is being developed to treat spasticity (muscle tightness) in MS, and MMJ-002 to treat Huntington’s-associated chorea — a neurological disorder marked by involuntary jerky movements, especially in the shoulders, hips, and face.

Both medications contain THC and CBD, two of the most abundant cannabinoids found in the cannabis plant. CBD is a non-psychoactive component of cannabis and believed to have neuro-protective properties, while THC is the main psychoactive constituent of cannabis.

MMJ-002 was designated an orphan drug by the the U.S. Food and Drug Administration (FDA) in January as a

... read more at: https://multiplesclerosisnewstoday.com/news-posts/2019/08/12/mmj-international-holdings-shipping-thc-and-cbd-to-us-for-clinical-trials/

by

Leave a Reply

To Support MS Cannabinoid Studies, MMJ Asks US Agency to OK Shipments from Canada

MMJ International Holdings, a pharmaceutical company whose focus is plant-derived cannabis products for therapeutic purposes, has requested permission to ship tetrahydrocannabinol (THC) and cannabidiol (CBD) from Canada to the U.S. to be used in upcoming clinical trials for people with multiple sclerosis (MS) and Huntington’s disease.

MMJ-001 and MMJ-002 are among the company’s lead therapeutic candidates. MMJ-001 is being developed to treat spasticity (muscle tightness) in MS, and MMJ-002 to treat Huntington’s-associated chorea — a neurological disorder marked by involuntary jerky movements, especially in the shoulders, hips, and face.

Both medications contain THC and CBD, two of the most abundant cannabinoids found in the cannabis plant. CBD is a non-psychoactive component of cannabis and believed to have neuro-protective properties, while THC is the main psychoactive constituent of cannabis.

MMJ-002 was designated an orphan drug by the the U.S. Food and Drug Administration (FDA) in January as a

... read more at: https://multiplesclerosisnewstoday.com/news-posts/2019/08/12/mmj-international-holdings-shipping-thc-and-cbd-to-us-for-clinical-trials/

by

Leave a Reply